NasdaqGS:AUTLBiotechs
Autolus Therapeutics (AUTL) Loss Deepens To US$79.1 Million Challenging Bullish Profitability Narratives
Autolus Therapeutics (AUTL) has reported another loss-making quarter, with Q3 FY 2025 revenue of US$21.2 million and basic EPS of a US$0.30 loss, alongside a net income loss of US$79.1 million. The company’s quarterly revenue has moved from US$0.03 million in Q4 FY 2024 to US$9.0 million in Q1 FY 2025, US$20.9 million in Q2, and US$21.2 million in Q3. Over the same period, basic EPS has ranged between a US$0.10 loss and a US$0.31 loss, highlighting a clear tension between a growing top line...